How Sick Will Brexit Make Biotech and Pharma?

Source: Tracy Salcedo of The Life Sciences Report  (06/29/2016)
How Sick Will Brexit Make Biotech and Pharma?
Given the uncertainty and dire economic forecasts following the Brexit vote, The Life Sciences Report has reviewed commentary from sector experts and biotech publications to help investors understand what Brexit might mean for the industry. read more >

Partnerships Propel Stellar Biotechnologies' Vaccine Technology

Source: Tracy Salcedo of The Life Sciences Report  (06/22/2016)
Partnerships Propel Stellar Biotechnologies' Vaccine Technology
Maxim analyst Jason McCarthy sees nothing but blue sky for Stellar Biotechnologies Inc. With blockbuster indications like cancer, lupus and Alzheimer's disease being targeted by partners, and a manufacturing process sure to satisfy regulators, McCarthy lays out a value proposition for Stellar's KLH that investors should not ignore. read more >

Soligenix Develops Defenses Against Bioterrorism

Source: Staff of The Life Sciences Report  (06/15/2016)
Soligenix Develops Defenses Against Bioterrorism
Maxim Group biotech analyst Jason Kolbert notes "steady progress" is being made by Soligenix Inc., a small-cap biotech with programs addressing bioterrorism threats and a devastating side effect of cancer treatment, in his Q1/16 update on the company. read more >

Investment in Cell and Gene Therapies Ramps Up

Source: George S. Mack of The Life Sciences Report  (06/08/2016)
Investment in Cell and Gene Therapies Ramps Up
After decades of disappointment, cell therapies and gene therapies are finally seeing light at the end of the tunnel. Investors, investigators, clinicians, and patients with serious unmet needs are watching pivotal trials move into the home stretch. Yes. . .pivotal data are actually on the way. read more >
Management Q&A: View from the Top

OncoSec Delivers Cancer Therapy Straight to the Tumor

Managment Q&A: View from the Top
Source: Special to The Life Sciences Report  (06/01/2016)
OncoSec Delivers Cancer Therapy Straight to the Tumor
Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated's Punit Dhillon describes how his company is using a proprietary platform to deliver therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies. read more >
Management Q&A: View from the Top

How Nobilis Health Will Break Out of the Healthcare Payment Mold

Managment Q&A: View from the Top
Source: George S. Mack of The Life Sciences Report   (05/25/2016)
How Nobilis Health Will Break Out of the Healthcare Payment Mold
Managing both acquisitions and internal growth at the same time is difficult for most small companies, but not for Nobilis Health Corp., which is orchestrating the flow of new patients to its ambulatory surgical centers while it adds an ensemble of new clinics, resulting in harmonious revenue. read more >

With Potential Vaccines for Cancer, Ebola and Zika, Inovio Could Have an Explosive 2016

Source: The Life Sciences Report  (05/18/2016)
With Potential Vaccines for Cancer, Ebola and Zika, Inovio Could Have an Explosive 2016
Recent news from Inovio Pharmaceuticals Inc., a small-cap biotech developing immunotherapeutic vaccines that target cancer and infectious diseases like news-making viruses Ebola and Zika, has prompted Piper Jaffray analyst Charles Duncan to reiterate his thesis for investment in the company. read more >
Expert Investing Ideas

"HLTH reported solid revenue growth for Q1/16."

–William Sutherland, Emerging Growth Equities Ltd.


NASDAQ Biotech ARCA Pharmaceutical
Management Q&A: View from the Top

Dialing Back Euphoria: The Intellipharmaceutics Prescription for Opioid Abuse

Managment Q&A: View from the Top
Source: Special to The Life Sciences Report  (05/11/2016)
Dialing Back Euphoria: The Intellipharmaceutics Prescription for Opioid Abuse
Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers run a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International has a potential solution. read more >

Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology

Source: George S. Mack of The Life Sciences Report  (05/11/2016)
Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
Unmet medical needs exist all over the globe, creating a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare analyst Dennis Hulme of Edison Investment Research cites a group of Australian medtech and biotech names that investors should look at very carefully. read more >
Management Q&A: View from the Top

Exosome Sciences Uncovers Biomarker Candidate to ID Players with CTE

Managment Q&A: View from the Top
Source: Special to The Life Sciences Report  (05/04/2016)
Exosome Sciences Uncovers Biomarker Candidate to ID Players with CTE
Executive Chairman James "Jim" Joyce of Exosome Sciences, a subsidiary of Aethlon Medical Inc., shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. read more >

Delving Deep into Immune Pharmaceuticals' Diverse Pipeline

Contributed Opinion
Source: Jason Napodano  (05/04/2016)
Delving Deep into Immune Pharmaceuticals' Diverse Pipeline
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer. The company has several active clinical programs, led by bertilimumab, which is in Phase 2 for the treatment of inflammatory bowel disease and skin disorders. Analyst Jason Napodano digs into the company's pipeline and investment potential. read more >
Biotech Watchlist 2016